BMS looks to new prod­uct port­fo­lio as rev­enues slide due to Revlim­id loss­es

Bris­tol My­ers Squibb cit­ed low­er Revlim­id sales as a dri­ver of its falling rev­enue in the US in the sec­ond quar­ter of 2023.

The can­cer drug brought in just un­der $1.47 bil­lion in Q2, down 41% from the same time last year due to gener­ic com­pe­ti­tion and a greater num­ber of pa­tients ac­cess­ing the drug through an as­sis­tance pro­gram. The com­pa­ny’s over­all rev­enue was $11.2 bil­lion, down 6% from last year, caus­ing Bris­tol My­ers to re­vise its full-year guid­ance. While it pre­vi­ous­ly an­tic­i­pat­ed a rough­ly 2% in­crease in rev­enues, it’s now call­ing for a “low sin­gle dig­it de­cline.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER